BMO cuts Zimmer Biomet stock price target on debt refinancing costs
BMO Capital reduced its price target for Zimmer Biomet (ZBH) to $101 from $102, citing higher debt refinancing costs. The company issued €500M and $500M in notes, adding ~$17M in annual interest expense. ZBH's Q3 2026 revenue was $2.06B, beating estimates, with EPS flat at $1.90. Analysts adjusted targets, with Stifel at $140 and Jefferies at $120.
How this was made
The 30-second read
Why it matters
BMO’s target reduction is driven by estimated incremental annual interest expense (~$17M) and a small reduction in 2027 EPS estimate ($8.78 vs $8.85), implying a near-term earnings headwind from refinancing costs.
Market read
Traders may adjust expectations for ZBH’s earnings trajectory and valuation sensitivity to refinancing costs following the analyst’s updated model inputs.
What to watch
The offering materials do not specify use of proceeds; if proceeds refinance maturities efficiently or extend duration, the long-run balance-sheet impact could be less negative than the incremental interest expense implies.
Background
Zimmer Biomet announced a dual-currency debt offering on Nov 12, issuing €500M 4.375% notes due 2033 and $500M 5.850% notes due 2036.
Ticker impact
BMO cut Zimmer Biomet’s price target to $101 after the company announced a dual-currency debt offering that raises annual interest expense.
Likely modest downside bias as the market prices higher interest expense and the reduced 2027 EPS outlook.
The article ties the target cut directly to incremental annual interest expense (~$17M) and a reduced 2027 EPS estimate, both of which affect near-term earnings power and valuation.
Market effects
Medical device peers with similar leverage/refinancing profiles may see read-across on interest-rate sensitivity and valuation multiples.
Limited, primarily affects US large-cap medical device sentiment rather than broad regional risk.
Euro and USD note issuance highlights cross-currency funding conditions, but the impact is company-specific.
Counterpoint
The article notes InvestingPro still flags ZBH as undervalued versus fair value, suggesting the target cut may be more about near-term EPS optics than long-term fundamentals.
Key entities
- companyZimmer Biomet Holdings Inc.
Subject of the analyst price-target cut tied to debt refinancing costs and updated EPS estimates.
- analyst_firmBMO Capital
Lowered ZBH price target to $101 from $102 while maintaining Market Perform.


